Astria Therapeutics, Inc. (ATXS) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
H.C. Wainwright Reiterates Buy Rating on Astria Therapeutics (ATXS)
August 13, 2024 6:04 AM EDTH.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $16.00 price target on Astria Therapeutics (NASDAQ: ATXS).
The analyst comments "Clinical development of navenibart and STAR-0310 backed by positive marks and new partners. Following favorable initial proof-of-concept data from the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215) in patients with hereditary angioedema (HAE), and pending regulatory feedback, the company plans to initiate a Phase 3 study in 1Q25, with top-line data expected by YE26. Recall, ALPHA-STAR... More
